Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Chloroform. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL241751 | 1.00 | — | — | |
| Chloroform SCHEMBL4395340 | 1.00 | LMNA (0.44) | — | |
| Chloroform SCHEMBL28063298 | 0.94 | LMNA (0.50) | — | |
| Chloroform SCHEMBL134683 | 0.94 | — | — | |
| Chloroform SCHEMBL28040546 | 0.94 | — | — | |
| Chloroform SCHEMBL27706310 | 0.94 | LMNA (0.50) | — | |
| Chloroform SCHEMBL8907442 | 0.94 | LMNA (0.50) | — | |
| Chloroform SCHEMBL9617984 | 0.94 | LMNA (0.50) | — | |
| Chloroform SCHEMBL4318431 | 0.94 | — | — | |
| Chloroform SCHEMBL25447 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240033346-A1 | VACCINE COMPOSITION FOR CHICKENPOX OR VARICELLA ZOSTER AND METHOD OF USING SAME | EUBIOLOGICS CO., LTD. (KR) | 2024-02-01 | — | — | US | disclosed |
| EP-4212173-A1 | VACCINE COMPOSITION FOR CHICKENPOX OR VARICELLA ZOSTER AND METHOD OF USING SAME | Eubiologics Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220409641-A1 | PHOSPHOLIPID COMPOSITIONS | MACHAVERT PHARMACEUTICALS LLC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220395486-A1 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-15 | — | — | US | disclosed |
| US-20220259633-A1 | METHOD FOR PRODUCING MONOPHOSPHORYL LIPID A | EUBIOLOGICS CO., LTD. (KR) | 2022-08-18 | — | — | US | disclosed |
| US-20220168402-A1 | PIP4Ks SUPPRESS INSULIN SIGNALING AND ENHANCE IMMUNE FUNCTION THROUGH A CATALYTIC-INDEPENDENT MECHANISM | CORNELL UNIVERSITY | 2022-06-02 | — | — | US | disclosed |
| US-11266626-B2 | Reduction of ER-MAM-localized APP-C99 and methods of treating alzheimer's disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3953394-A1 | PIP4KS SUPPRESS INSULIN SIGNALING AND ENHANCE IMMUNE FUNCTION THROUGH A CATALYTIC-INDEPENDENT MECHANISM | Cornell University (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021040414-A1 | METHOD FOR PRODUCING MONOPHOSPHORYL LIPID A | 주식회사 유바이오로직스 | 2021-03-04 | — | — | WO | disclosed |
| WO-2020247815-A1 | TRANSGENIC RODENT MODEL FOR LUNG FIBROSIS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-4912094-A | Removal hydroxymyristic acyl residue | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0324455-A2 | Novel polymeric immunological adjuvants | Ribi, Hans O. (US) | 1989-07-19 | — | — | EP | disclosed |
| US-4782043-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | disclosed |
| US-4737517-A | Coumarin derivatives, pharmaceutical compositions containing the same, and the use thereof in the treatment of cancer | FIDIA, S.P.A. (IT) | 1988-04-12 | — | — | US | disclosed |
| US-4665052-A | HOMOPHENYLALANINE, HYPOTENSIVES, ANTIALDOSTERONES | MERCK & CO., INC. (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
| US-4485099-A | HYPOTENSIVE AGENTS/,ANTIALDOSTERONES | MERCK & CO., INC. (US) | 1984-11-27 | — | — | US | disclosed |
| EP-0104348-A2 | Fluorinated cyclic hexapeptide somatostatin analogs, process for their preparation, intermediate products for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1984-04-04 | — | — | EP | disclosed |
| US-4427661-A | ENZYME INHIBITORS FOR GLUCAGON AND INSULIN, GROWTH REGULATORS, ANTISECRETORY, ANTIULCER AND ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1984-01-24 | — | — | US | disclosed |
| US-4002742-A | 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor | SCHERING CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |